What is the recommended dose of capmatinib per dose?

Capmatinib is a targeted drug that is mainly used to treat patients with non-small cell lung cancer (NSCLC) with MET gene mutations, especially in patients with METex14 mutations. The recommended dose of capmatinib depends on the patient's specific condition, but in general, for adult patients, the recommended dose of capmatinib is 400 mg orally once daily. This dose was determined based on clinical trial data of capmatinib and aims to achieve sufficient drug concentration to effectively inhibit the MET signaling pathway in tumor cells.

In clinical use, capmatinib should be appropriately adjusted according to the patient's tolerance. For example, if a patient develops severe liver damage or other serious side effects, the dose may need to be reduced or use suspended. In addition, patients need to undergo regular blood tests and liver function tests while taking capmatinib to ensure the safety and effectiveness of the drug. For patients without significant hepatic impairment, the recommended dose is 400 mg once daily.

It is worth noting that there are certain requirements for the way capmatinib is taken. The drug should be taken orally at a fixed time each day, preferably before or after meals, and patients should try to avoid missing or missed doses. If a patient misses a dose, they should try to avoid refilling the dose near the next dose to prevent the drug concentration from being too high, leading to adverse reactions. When taking capmatinib, patients need to stay adequately hydrated and continue to monitor the drug's efficacy and side effects under the guidance of a doctor.

In clinical treatment, the dose of capmatinib is usually adjusted according to the patient's specific conditions. If mild adverse reactions occur, your doctor may recommend reducing the dose or temporarily discontinuing the medication until symptoms resolve. For some patients with weak liver function, dose adjustment should be more cautious to avoid drug-induced liver damage.

Reference materials:https://www.novartis.com/our-products/pipeline/capmatinib